This move is archived. Current quotes and coverage live on the stock page.
Get EPRX alerts:
Eupraxia Pharmaceuticals Inc (EPRX.TO) saw a notable increase in its stock price, closing up 3.97% in the latest trading session.
In a market that often swings with the latest news, Eupraxia Pharmaceuticals has emerged as a standout performer on the TSX. With a closing price of CA$9.17, this recent uptick reflects growing investor confidence in the company's future prospects.
Advertisement
Eupraxia Pharmaceuticals Inc
EPRX.TO
EPRX.TO
Eupraxia Pharmaceuticals Inc
WealthAwesomeMarket cap
$769.09M
52W high
$12.86
52W low
$7.15
1W change
+1.87%
Beta
1.49
Analyst Price Targets
Based on analyst covering EPRX
Wall Street analysts forecast EPRX stock price to rise 54.4% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$16.00
+54.4% Upside
Current Price
C$10.36
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on EPRX's historical volatility
30-Day Vol
74.8%
Annualized
90-Day Vol
64.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$12.39
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$11.00 | C$8.49 โ C$14.23 |
| 60 trading days | C$11.67 | C$8.10 โ C$16.81 |
| 90 trading days | C$12.39 | C$7.92 โ C$19.37 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Eupraxia's rise today signals positive sentiment among investors, likely driven by its ongoing clinical developments and strong financial backing.
Eupraxia Pharmaceuticals Inc Gains 3.97% in One Day
The stock's increase reflects a growing optimism among investors, likely linked to its clinical advancements and financial stability.
Bull case
Eupraxia recently reported a strong response in its EP-104GI treatment cohort. With over $140 million in cash, the company is well-positioned to fund its clinical trials and explore additional indications.
Bear case
Despite today's gains, Eupraxia's past financial results show a significant net loss, raising concerns about its long-term profitability and the sustainability of its growth.
Eupraxia's Clinical Developments
Advertisement
Eupraxia Pharmaceuticals has been making strides in its clinical programs, particularly with the EP-104GI treatment. Recent reports indicate a promising response in the highest dose cohort, which may drive further investor interest and confidence in the company's potential.
Financial Position and Market Confidence
With a market cap of CA$576 million and over $140 million in cash, Eupraxia is well-capitalized to support its ongoing clinical trials. This financial stability is crucial as it allows the company to focus on its long-term growth strategy without immediate funding pressures.
Looking Ahead
As Eupraxia Pharmaceuticals continues to advance its clinical trials and explore new indications, investors will be closely monitoring the company's progress. Today's stock rise may be just the beginning if the company can maintain momentum in its developments.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
